Understanding Tysabri and PML: What the Clinical Evidence Shows

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Risk Awareness

If you or a loved one is taking Tysabri and concerned about the risk of progressive multifocal leukoencephalopathy (PML), understanding the diagnostic process is essential. The medical community has built a substantial body of research on PML detection and monitoring in patients on biologic therapies. This page provides an overview of the clinical evaluation and safety considerations surrounding Tysabri and PML.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a severe demyelinating disease that typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning identifies three risk factors for developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Monitoring of PML

The clinical presentation of PML can be variable. A large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). In that cohort, 376 cases (82.4%) had a definite diagnosis and 80 (17.6%) had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study noted changing characteristics of PML over time and according to underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/). For patients on Tysabri, healthcare professionals are instructed to monitor for any new sign or symptom that may be suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adverse Event Reports and Mechanistic Pathway

Adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) most frequently associated with Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), multiple sclerosis (9,580 reports), gait disturbance (9,422 reports), fall (7,939 reports), memory impairment (7,895 reports), asthenia (7,852 reports), malaise (7,319 reports), drug ineffective (6,813 reports), urinary tract infection (6,192 reports), pain (5,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), pain in extremity (4,849 reports), muscular weakness (4,535 reports), nasopharyngitis (4,423 reports), nausea (4,203 reports), dizziness (3,944 reports), mobility decreased (3,769 reports), stress (3,542 reports), cognitive disorder (3,478 reports), muscle spasms (3,152 reports), depression (3,091 reports), and arthralgia (2,992 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the range of adverse events observed in clinical use. The mechanistic pathway linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the central nervous system. This action reduces inflammation in multiple sclerosis but also impairs the immune system's ability to control JC virus reactivation in the brain. The JC virus can then replicate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Affected Individuals

Regarding the adequacy of warnings, the boxed warning on the Tysabri label explicitly states that the drug increases the risk of PML and describes the known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also instructs healthcare professionals to monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program is a restricted distribution program designed to ensure that the risks are communicated and managed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, patients who develop PML may face severe outcomes, including death or permanent disability. For affected patients and their families, attorney-related considerations may include evaluating whether the warnings provided were adequate and whether the patient's specific risk factors were properly assessed and communicated. The timeline between exposure to Tysabri and documented harm is critical. PML can develop after varying durations of treatment, with risk increasing beyond two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early symptoms of PML may be subtle and include cognitive changes, motor deficits, or visual disturbances, which can be mistaken for multiple sclerosis relapse. Delayed diagnosis can worsen outcomes. Patients who experience PML may need to pursue legal action to seek compensation for medical expenses, lost income, and pain and suffering. An attorney experienced in pharmaceutical litigation can help assess the case, gather medical records, and determine whether the manufacturer failed to provide adequate warnings or whether the prescribing physician deviated from standard of care.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it increase the risk of PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug works by inhibiting lymphocyte migration into the central nervous system, which can impair immune surveillance and allow JC virus reactivation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The boxed warning identifies three risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What should I do if I or a loved one developed PML after Tysabri treatment?

Seek immediate medical attention. You may also wish to consult an attorney experienced in pharmaceutical litigation to evaluate whether the warnings were adequate and whether legal action for compensation is appropriate.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.